IL147863A0 - Tricyclic inhibitors of poly (adp-ribose) polymerases - Google Patents

Tricyclic inhibitors of poly (adp-ribose) polymerases

Info

Publication number
IL147863A0
IL147863A0 IL14786300A IL14786300A IL147863A0 IL 147863 A0 IL147863 A0 IL 147863A0 IL 14786300 A IL14786300 A IL 14786300A IL 14786300 A IL14786300 A IL 14786300A IL 147863 A0 IL147863 A0 IL 147863A0
Authority
IL
Israel
Prior art keywords
polymerases
adp
ribose
poly
tricyclic inhibitors
Prior art date
Application number
IL14786300A
Other languages
English (en)
Original Assignee
Agouron Pharma
Cancer Campaign Technology Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agouron Pharma, Cancer Campaign Technology Ltd filed Critical Agouron Pharma
Publication of IL147863A0 publication Critical patent/IL147863A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/06—Peri-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IL14786300A 1999-08-31 2000-08-31 Tricyclic inhibitors of poly (adp-ribose) polymerases IL147863A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15214299P 1999-08-31 1999-08-31
PCT/US2000/023882 WO2001016136A2 (en) 1999-08-31 2000-08-31 Tricyclic inhibitors of poly(adp-ribose) polymerases

Publications (1)

Publication Number Publication Date
IL147863A0 true IL147863A0 (en) 2002-08-14

Family

ID=22541675

Family Applications (1)

Application Number Title Priority Date Filing Date
IL14786300A IL147863A0 (en) 1999-08-31 2000-08-31 Tricyclic inhibitors of poly (adp-ribose) polymerases

Country Status (48)

Country Link
US (1) US6548494B1 (hu)
EP (1) EP1208104B1 (hu)
JP (1) JP4272375B2 (hu)
KR (1) KR20020038742A (hu)
CN (1) CN1384835A (hu)
AP (1) AP1553A (hu)
AR (1) AR035162A1 (hu)
AT (1) ATE287406T1 (hu)
AU (1) AU781826B2 (hu)
BG (1) BG106562A (hu)
BR (1) BR0015051A (hu)
CA (1) CA2382404C (hu)
CO (1) CO5200769A1 (hu)
CR (1) CR6577A (hu)
CZ (1) CZ2002613A3 (hu)
DE (1) DE60017575T2 (hu)
DK (1) DK1208104T3 (hu)
DO (1) DOP2000000069A (hu)
DZ (1) DZ3216A1 (hu)
EA (1) EA200200306A1 (hu)
EC (1) ECSP003637A (hu)
EE (1) EE200200100A (hu)
ES (1) ES2234657T3 (hu)
GE (1) GEP20043268B (hu)
GT (1) GT200000145A (hu)
HK (1) HK1045509B (hu)
HR (1) HRP20020271A2 (hu)
HU (1) HUP0202703A3 (hu)
IL (1) IL147863A0 (hu)
IS (1) IS6289A (hu)
MA (1) MA25876A1 (hu)
MX (1) MXPA02002138A (hu)
MY (1) MY135910A (hu)
NO (1) NO322475B1 (hu)
NZ (1) NZ516793A (hu)
OA (1) OA12016A (hu)
PA (1) PA8501801A1 (hu)
PE (1) PE20010538A1 (hu)
PL (1) PL354242A1 (hu)
PT (1) PT1208104E (hu)
SI (1) SI1208104T1 (hu)
SK (1) SK2592002A3 (hu)
SV (1) SV2003000162A (hu)
UA (1) UA73144C2 (hu)
UY (1) UY26323A1 (hu)
WO (1) WO2001016136A2 (hu)
YU (1) YU15102A (hu)
ZA (1) ZA200200830B (hu)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003510328A (ja) * 1999-09-28 2003-03-18 ビーエーエスエフ アクチェンゲゼルシャフト アゼピノインドール誘導体、その製法ならびに使用
DE19946289A1 (de) * 1999-09-28 2001-03-29 Basf Ag Benzodiazepin-Derivate, deren Herstellung und Anwendung
DE10021468A1 (de) * 2000-05-04 2001-11-08 Basf Ag Verwendung von PARP-Inhibitoren in kosmetischen Zubereitungen
US7151102B2 (en) 2000-10-30 2006-12-19 Kudos Pharmaceuticals Limited Phthalazinone derivatives
FR2816942B1 (fr) * 2000-11-23 2003-05-09 Sanofi Synthelabo Derives de benzimidazole, leur preparation et leur application en therapeutique
WO2003051879A1 (en) * 2001-12-14 2003-06-26 Altana Pharma Ag Known and novel 4,5-dihydro-imidazo[4,5,1-ij]quinolin-6-ones useful as poly(adp-ribose)polymerase inhibitors
US7026311B2 (en) 2002-01-10 2006-04-11 Abbott Gmbh & Co., Kg Dibenzodiazepine derivatives, their preparation and use
EP1501822B1 (en) 2002-04-30 2010-12-15 Kudos Pharmaceuticals Limited Phthalazinone derivatives
AU2003236686A1 (en) * 2002-06-07 2003-12-22 Altana Pharma Ag 4,5-dihydro-imidazo(4,5,1-j) quinolin-6-ones as parp inhibitors
AU2004203977B2 (en) 2003-01-09 2010-06-17 Pfizer Inc. Diazepinoindole derivatives as kinase inhibitors
US7449464B2 (en) 2003-03-12 2008-11-11 Kudos Pharmaceuticals Limited Phthalazinone derivatives
GB0305681D0 (en) 2003-03-12 2003-04-16 Kudos Pharm Ltd Phthalazinone derivatives
GB0317466D0 (en) 2003-07-25 2003-08-27 Univ Sheffield Use
PL1660095T3 (pl) * 2003-07-25 2010-07-30 Cancer Research Tech Ltd Tricykliczne inhibitory PARP
WO2005035534A1 (ja) * 2003-10-08 2005-04-21 Ono Pharmaceutical Co., Ltd. 複素ビシクロ環および複素トリシクロ環化合物およびその医薬
ATE521341T1 (de) 2003-12-01 2011-09-15 Kudos Pharm Ltd Dna-schäden-reparatur-hemmer zur behandlung von krebs
WO2006033003A1 (en) * 2004-09-22 2006-03-30 Pfizer, Inc. Method of preparing poly(adp-ribose) polymerases inhibitors
EP1841771A4 (en) * 2005-01-19 2008-09-24 Mgi Gp Inc COMPOUNDS OF DIAZABENZO [DE] ANTHRACENE-3-ONE AND USE IN INHIBITION OF PARP
EP1902057B1 (en) 2005-06-14 2013-10-23 Merck Sharp & Dohme Corp. Macrocyclic heterocyclic aspartyl protease inhibitors
US20090226412A1 (en) * 2005-06-24 2009-09-10 Ono Pharmaceutical Co., Ltd., Agent for reduction of bleeding in cerebrovascular disorder
WO2007011962A2 (en) * 2005-07-18 2007-01-25 Bipar Sciences, Inc. Treatment of cancer
CA2616020A1 (en) * 2005-08-05 2007-02-15 Astrazeneca Ab Tricyclic benzimidazoles and their use as metabotropic glutamate receptor modulators
GB0521373D0 (en) 2005-10-20 2005-11-30 Kudos Pharm Ltd Pthalazinone derivatives
US20100279327A1 (en) * 2006-06-12 2010-11-04 Bipar Sciences, Inc. Method of treating diseases with parp inhibitors
US20080262062A1 (en) * 2006-11-20 2008-10-23 Bipar Sciences, Inc. Method of treating diseases with parp inhibitors
JP2010504079A (ja) * 2006-06-12 2010-02-12 バイパー サイエンシズ，インコーポレイティド Ｐａｒｐ阻害剤を用いる疾病の治療方法
US8143447B2 (en) * 2006-09-05 2012-03-27 Bipar Sciences, Inc. Treatment of cancer
AU2007292306A1 (en) * 2006-09-05 2008-03-13 Bipar Sciences, Inc. Inhibition of fatty acid synthesis by PARP inhibitors and methods of treatment thereof
TWI404716B (zh) 2006-10-17 2013-08-11 Kudos Pharm Ltd 酞嗪酮（ｐｈｔｈａｌａｚｉｎｏｎｅ）衍生物
CN101808987A (zh) 2007-06-05 2010-08-18 Nsab神经研究瑞典公司分公司 作为皮层儿茶酚胺能神经传递调节剂的二取代的苯基吡咯烷
WO2008154129A1 (en) * 2007-06-08 2008-12-18 Bausch & Lomb Incorporated Pharmaceutical compositions and method for treating, reducing, ameliorating, alleviating, or preventing dry eye
JP2010539149A (ja) 2007-09-14 2010-12-16 アストラゼネカ アクチボラグ フタラジノン誘導体
NZ586123A (en) * 2007-11-12 2012-12-21 Bipar Sciences Inc Treatment of ovarian cancer with 4-iodo-3-nitrobenzamide in combination with topoisomerase inhibitors
EP2217227B1 (en) * 2007-11-12 2013-08-21 BiPar Sciences, Inc. Treatment of breast cancer with 4-iodo-3-nitrobenzamide in combination with anti-tumor agents
RU2010128107A (ru) * 2007-12-07 2012-01-20 Байпар Сайенсиз, Инк. (Us) Лечение рака ингибиторами топоизомеразы в комбинации с ингибиторами parp
UY31603A1 (es) 2008-01-23 2009-08-31 Derivados de ftalazinona
CN101999002A (zh) * 2008-02-04 2011-03-30 彼帕科学公司 诊断和治疗parp-介导的疾病的方法
GB0804755D0 (en) 2008-03-14 2008-04-16 Angeletti P Ist Richerche Bio Therapeutic compounds
JP5524220B2 (ja) 2008-10-07 2014-06-18 アストラゼネカ・ユーケイ・リミテッド 医薬配合物５１４
WO2011058367A2 (en) 2009-11-13 2011-05-19 Astrazeneca Ab Diagnostic test for predicting responsiveness to treatment with poly(adp-ribose) polymerase (parp) inhibitor
US20150218110A1 (en) * 2012-09-05 2015-08-06 Bayer Cropscience Ag Use of substituted benzodiazepinones and benzazepinones or the salts thereof as active substances against abiotic plant stress
JP6407303B2 (ja) * 2014-01-05 2018-10-17 ワシントン・ユニバーシティＷａｓｈｉｎｇｔｏｎ Ｕｎｉｖｅｒｓｉｔｙ ポリ（ａｄｐ−リボース）ポリメラーゼ−１（ｐａｒｐ−１）のための放射標識トレーサー、その方法および使用
WO2017013237A1 (en) 2015-07-23 2017-01-26 Institut Curie Use of a combination of dbait molecule and parp inhibitors to treat cancer
GB201519573D0 (en) 2015-11-05 2015-12-23 King S College London Combination
US10874641B2 (en) 2016-07-28 2020-12-29 Mitobridge, Inc. Methods of treating acute kidney injury
CN110300600A (zh) 2016-11-02 2019-10-01 伊缪诺金公司 利用抗体-药物缀合物和parp抑制剂的组合治疗
WO2018162439A1 (en) 2017-03-08 2018-09-13 Onxeo New predictive biomarker for the sensitivity to a treatment of cancer with a dbait molecule
AU2018260094A1 (en) 2017-04-28 2019-11-07 Akribes Biomedical Gmbh A PARP inhibitor in combination with a glucocorticoid and/or ascorbic acid and/or a protein growth factor for the treatment of impaired wound healing
AU2019205325A1 (en) 2018-01-05 2020-08-13 Cybrexa 1, Inc. Compounds, compositions, and methods for treatment of diseases involving acidic or hypoxic diseased tissues
JP2021515580A (ja) 2018-03-13 2021-06-24 オンクセオＯｎｘｅｏ がんの治療における獲得耐性に対抗するｄｂａｉｔ分子
JP2021530442A (ja) * 2018-06-28 2021-11-11 ジエンス ヘンルイ メデイシンカンパニー リミテッドJiangsu Hengrui Medicine Co., Ltd. 縮合三環系複素環化合物およびその治療上の使用
CN112552314B (zh) * 2018-08-24 2022-03-04 杭州阿诺生物医药科技有限公司 Sting激动剂小分子抗肿瘤化合物及其应用
JP2022511540A (ja) * 2018-12-14 2022-01-31 ジエンス ヘンルイ メデイシンカンパニー リミテッド Ｓｔｉｎｇアゴニストとしての三環式化合物、ならびにその調製方法および医薬用途
TW202116778A (zh) 2019-07-10 2021-05-01 美商斯布雷克薩二號公司 作為治療劑之細胞毒素之肽結合物
CN114302744A (zh) 2019-07-10 2022-04-08 赛博克萨3公司 作为治疗剂的微管靶向剂的肽缀合物
GB201913030D0 (en) 2019-09-10 2019-10-23 Francis Crick Institute Ltd Treatment of hr deficient cancer
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
CN115485271A (zh) 2020-04-28 2022-12-16 理森制药股份公司 用作聚(adp-核糖)聚合酶（parp）抑制剂的新型化合物
WO2022090938A1 (en) 2020-10-31 2022-05-05 Rhizen Pharmaceuticals Ag Phthalazinone derivatives useful as parp inhibitors
AU2022206297A1 (en) 2021-01-08 2023-08-03 Cybrexa 2, Inc. Process for preparing a conjugate linking moiety
WO2022155172A1 (en) 2021-01-13 2022-07-21 Cybrexa 3, Inc. Peptide conjugates of therapeutics
CA3214298A1 (en) 2021-04-08 2022-10-13 Swaroop Kumar Venkata Satya VAKKALANKA Inhibitors of poly(adp-ribose) polymerase

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1052390A (hu) 1964-03-24
US3734919A (en) * 1969-11-03 1973-05-22 Upjohn Co 4,5-di-hydropyrrolo(3,2,1-jk)(1,4)benzodiazepin-7(6h)-ones and 4,5-di-hydropyrrolo(1,2,3-ef)(1,5)benzodiazepin-6(7h)-ones
US3642820A (en) * 1969-11-03 1972-02-15 Upjohn Co 4 5-dihydropyrrolo(3 2 1-jk)(1 4)bezodiazepines
DE2056215A1 (de) 1970-11-16 1972-05-18 Farbwerke Hoechst AG, vorm. Meister Lucius & Brüning, 6000 Frankfurt Verfahren zur Herstellung von N-Mono-(beta-Cyanäthyl>anilinen
US3883590A (en) 1971-06-01 1975-05-13 Universal Oil Prod Co Preparation of n-alkylarylcarboxamides
US3950343A (en) 1973-11-06 1976-04-13 Ayerst, Mckenna And Harrison Ltd. Pyrroloisoquinoline derivatives
US3978066A (en) 1973-11-06 1976-08-31 Ayerst, Mckenna And Harrison Ltd. Certain 4,6-dihydropyrrolotriazoline-quinoline derivatives
US3900477A (en) 1973-11-06 1975-08-19 Ayerst Mckenna & Harrison 5-amino-and 5-hydrazinodihydropyrroloisoquinoline derivatives
JPS57144286A (en) 1981-03-02 1982-09-06 Takeda Chem Ind Ltd Azepinoindole derivative and its preparation
US4910193A (en) 1985-12-16 1990-03-20 Sandoz Ltd. Treatment of gastrointestinal disorders
DE4125292A1 (de) 1991-07-31 1993-02-04 Kali Chemie Pharma Gmbh 6-oxo-azepinoindol-verbindungen sowie verfahren und zwischenprodukte zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
US5342946A (en) 1992-12-02 1994-08-30 Guilford Pharmaceuticals Inc. Phosphonoalkylquinolin-2-ones as novel antagonists of non-NMDA ionotropic excitatory amino acid receptors
CN1114834A (zh) 1993-09-28 1996-01-10 大塚制药株式会社 抗糖尿病剂
US5587384A (en) 1994-02-04 1996-12-24 The Johns Hopkins University Inhibitors of poly(ADP-ribose) synthetase and use thereof to treat NMDA neurotoxicity
GB9404485D0 (en) 1994-03-09 1994-04-20 Cancer Res Campaign Tech Benzamide analogues
US5561161A (en) 1994-03-25 1996-10-01 Oxigene, Inc. Methods of administering and pharmaceutical formulations containing n-substituted benzamides and/or acid addition salts thereof
US5589483A (en) 1994-12-21 1996-12-31 Geron Corporation Isoquinoline poly (ADP-ribose) polymerase inhibitors to treat skin diseases associated with cellular senescence
ES2105959B1 (es) 1995-01-17 1998-07-01 Zeneca Pharma Sa Derivados de 1,4-dioxido de quinoxalina, procedimiento de preparacion y de utilizacion.
US5659082A (en) 1995-04-03 1997-08-19 Centaur Pharmaceuticals, Inc. Nitro- and aminobenzamide compounds for neurodegenerative disorders
US5756548A (en) 1995-04-03 1998-05-26 Centaur Pharmaceuticals, Inc. Acetamidobenzamide compounds for neurodegenerative disorders
AU714873B2 (en) * 1995-08-02 2000-01-13 Newcastle University Ventures Limited Benzimidazole compounds
HUT76302A (en) 1995-11-30 1997-07-28 Chinoin Gyogyszer Es Vegyeszet Quinoxaline derivatives, pharmaceutical compositions containing them and process for producing them
GB9702701D0 (en) 1997-02-01 1997-04-02 Univ Newcastle Ventures Ltd Quinazolinone compounds
CA2289119C (en) 1997-05-13 2011-03-15 Octamer, Inc. Methods for treating inflammation and inflammatory diseases using padprt inhibitors
US20020022636A1 (en) 1997-09-03 2002-02-21 Jia-He Li Oxo-substituted compounds, process of making, and compositions and methods for inhibiting parp activity
US6635642B1 (en) 1997-09-03 2003-10-21 Guilford Pharmaceuticals Inc. PARP inhibitors, pharmaceutical compositions comprising same, and methods of using same
AU9298098A (en) 1997-09-03 1999-03-22 Guilford Pharmaceuticals Inc. Amino-substituted compounds, methods, and compositions for inhibiting parp activity
US6514983B1 (en) 1997-09-03 2003-02-04 Guilford Pharmaceuticals Inc. Compounds, methods and pharmaceutical compositions for treating neural or cardiovascular tissue damage
US6197785B1 (en) 1997-09-03 2001-03-06 Guilford Pharmaceuticals Inc. Alkoxy-substituted compounds, methods, and compositions for inhibiting PARP activity
US20020028813A1 (en) 1997-09-03 2002-03-07 Paul F. Jackson Thioalkyl compounds, methods, and compositions for inhibiting parp activity
AU9298198A (en) 1997-09-03 1999-03-22 Guilford Pharmaceuticals Inc. Di-n-heterocyclic compounds, methods, and compositions for inhibiting parp activity
CA2332279A1 (en) 1998-05-15 1999-11-25 Jia-He Li Carboxamide compounds, compositions, and methods for inhibiting parp activity
JP2002515490A (ja) 1998-05-15 2002-05-28 ギルフォード ファーマシューティカルズ インコーポレイテッド Ｐａｒｐ活性を抑制する縮合三環化合物

Also Published As

Publication number Publication date
NZ516793A (en) 2004-03-26
NO20020421D0 (no) 2002-01-28
EP1208104B1 (en) 2005-01-19
HRP20020271A2 (en) 2005-12-31
NO322475B1 (no) 2006-10-09
SI1208104T1 (en) 2005-06-30
DOP2000000069A (es) 2002-08-30
AU7338900A (en) 2001-03-26
CA2382404C (en) 2009-03-24
HK1045509A1 (en) 2002-11-29
UY26323A1 (es) 2001-04-30
NO20020421L (no) 2002-04-25
DE60017575T2 (de) 2005-06-09
ZA200200830B (en) 2003-03-26
OA12016A (en) 2006-04-19
SV2003000162A (es) 2003-07-29
DZ3216A1 (fr) 2001-03-08
CO5200769A1 (es) 2002-09-27
DK1208104T3 (da) 2005-05-02
PA8501801A1 (es) 2002-08-26
BR0015051A (pt) 2002-06-25
EE200200100A (et) 2003-06-16
PL354242A1 (en) 2003-12-29
MXPA02002138A (es) 2003-08-20
MY135910A (en) 2008-07-31
GT200000145A (es) 2002-02-21
HUP0202703A3 (en) 2004-12-28
PE20010538A1 (es) 2001-05-22
CN1384835A (zh) 2002-12-11
ATE287406T1 (de) 2005-02-15
PT1208104E (pt) 2005-04-29
HUP0202703A2 (hu) 2002-12-28
DE60017575D1 (de) 2005-02-24
ES2234657T3 (es) 2005-07-01
EP1208104A2 (en) 2002-05-29
CR6577A (es) 2003-12-05
EA200200306A1 (ru) 2002-08-29
UA73144C2 (en) 2005-06-15
CA2382404A1 (en) 2001-03-08
KR20020038742A (ko) 2002-05-23
BG106562A (bg) 2003-03-31
IS6289A (is) 2002-02-27
AU781826B2 (en) 2005-06-16
JP4272375B2 (ja) 2009-06-03
ECSP003637A (es) 2002-03-25
WO2001016136B1 (en) 2001-11-15
GEP20043268B (en) 2004-06-25
AR035162A1 (es) 2004-05-05
WO2001016136A3 (en) 2001-06-21
CZ2002613A3 (cs) 2002-08-14
YU15102A (sh) 2004-12-31
US6548494B1 (en) 2003-04-15
WO2001016136A2 (en) 2001-03-08
MA25876A1 (fr) 2003-10-01
AP1553A (en) 2006-01-18
JP2003513015A (ja) 2003-04-08
HK1045509B (zh) 2005-04-29
SK2592002A3 (en) 2002-10-08

Similar Documents

Publication Publication Date Title
HK1040992A1 (en) Tricyclic inhibitors of poly(adp-ribose) polymerases
IL147863A0 (en) Tricyclic inhibitors of poly (adp-ribose) polymerases
IL145778A0 (en) Methods and compositions for inhibiting the function of polynucleotide sequences
GB2343691B (en) Isolation of subterranean zones
HK1041599A1 (en) Pyrrolotriazine inhibitors of kinases
EP1165084A4 (en) PRENYL PROTEIN TRANSFERASES INHIBITORS
EP1165082A4 (en) PRENYLE PROTEIN TRANSFERASE INHIBITORS
AU2954102A (en) (dihydro)isoquinoline derivatives as phosphodiesterase inhibitors
GB9930659D0 (en) Inhibitors of complement activation
PL351822A1 (en) Thienopyrimidines as phosphodiesterase inhibitors
AU2004200A (en) Poly(adp-ribose) polymerase inhibitors consisting of pyrimidine derivatives
EP1158982A4 (en) Prenyl protein transferase inhibitors
EP1221963A4 (en) METHODS OF INHIBITING OSTEOCLASTOGENESIS
EP1165013A4 (en) PRENYL PROTEIN TRANSFERASE INHIBITORS
EP1158983A4 (en) Prenyl protein transferase inhibitors
ZA200202868B (en) Use of thienopyrimidines.
IL133446A0 (en) Novel phenyl-substituted tricyclic inhibitors of farnesyl-protein transferase
GB9900148D0 (en) Inhibitors of prenyl-protein transferase
GB9900850D0 (en) Inhibitors of complement activation
GB9928772D0 (en) Inhibitors of complement activation
TW444702U (en) Structure of carrier rack